Skip to main navigation

Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb^®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
- News
- Publications
Careers
Corporate
Investors
Main navigation
Events
Presentations

Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
- News
- Publications
Investors
Main navigation
Events
Presentations
Careers
Contact Us
ActivMAb ^®

Science in the service of medicine

About
Pipeline
Clinical Trials
- Patients
- Physicians & Researchers

News & Publications
- News
- Publications
Investors
Main navigation
Events
Presentations
Careers
Contact Us
ActivMAb ^®

News Releases

News Releases

Investors

Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter

News Releases

Keyword Search

Year

09/28/23

Vaccinex Announces Pricing of $9.6 Million Public Offering

09/28/23

Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration

09/27/23

Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application

09/26/23

Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

09/22/23

Vaccinex, Inc. Announces Reverse Stock Split

08/14/23

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

06/01/23

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET

05/15/23

Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

04/25/23

Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab

04/12/23

Vaccinex New ActivMab® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells

04/03/23

Vaccinex Announces Private Placement with Commitments of $5.0 Million

04/03/23

Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs

03/23/23

Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference

03/21/23

Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

03/09/23

Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis

01/09/23

Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology

About
Pipeline
Clinical Trials

News
Careers
Contact

Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585-271-2700
F: 585-271-2765
info@vaccinex.com

© 2023 Vaccinex. All rights reserved
Privacy Policy
Site by Minerva